Skip to main content Accessibility help
×
Home

Health management of older persons with chronically medicated psychotic disorders: the results of a survey in France

  • Christophe Arbus (a1), Jean-Pierre Clement (a2), Thierry Bougerol (a3), Patrick Fremont (a4), Sylvie Lancrenon (a5) and Vincent Camus (a6)...

Abstract

Background: The medical care of elderly patients with psychotic disorders is a matter of major concern. The aim of the study was to investigate health conditions and treatment of elderly patients with psychotic disorders in France.

Methods: The SAGE (Schizophrenia AGEd) study (observational, cross-sectional) was a survey conducted among 123 physicians in France, regarding prescriptions of antipsychotic drugs in elderly patients (≥60 years) suffering from psychotic disorders. The survey was based on a questionnaire addressing the mental and somatic health management of the patients.

Results: Data from 930 patients (mean age: 70.4 years) were collected. Most patients (58.5%) suffered from schizophrenia, 20.8% had delusional disorder and 20.6% hallucinatory chronic psychosis (very-late-onset schizophrenia-like psychosis). 70.8% of them were outpatients, while 29.2% were inpatients. The severity of psychotic symptoms was assessed in 97.8% of patients, but cognitive function was only evaluated in 41.6%. Some 46.5% of patients were treated with atypical antipsychotics alone, 36.2% with classical antipsychotics alone and 17.3% received a combination of both, atypical and classical antipsychotics; 36.3% patients were given antiparkinsonian medication, of whom only 17.8% as preventive treatment; 51.1% of patients had somatic comorbidities, particularly cardiovascular disorders (34.0%). Evaluation of renal and/or liver function to adjust the dose of treatment was done in only 32.1% of patients. Over the previous 12 months, almost half of the patients had had no ECG, glycemia or creatininemia investigated and HDL-cholesterol and triglycerides were available for less than one-third of them.

Conclusions: Antipsychotic and antiparkinsonian drug prescriptions in French aged psychotic patients follow only partially the clinical guidelines and recommendations of consensus conferences. Moreover, cognitive, cardiac and metabolic aspects are not fully managed as expected.

Copyright

Corresponding author

Correspondence should be addressed to: Christophe Arbus, Department of Psychiatry and Medical Psychology, Purpan-Casselardit Hospital, 31059 Toulouse, France. Phone: +33 561772351; Fax: +33 561777646. Email: arbus.c@chu-toulouse.fr.

References

Hide All
Alexopoulos, G. S., Streim, J., Carpenter, D. and Docherty, J. P. for the Expert Consensus Panel for Using Antipsychotic Drugs in Older Patients (2004). Using antipsychotic agents in older patients. Journal of Clinical Psychiatry, 65 (Suppl. 2), 599.
Brodaty, H. et al. (2003). A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia. Journal of Clinical Psychiatry, 64, 134143.
Charles, M.-A. et al. (2008). Monitoring the obesity epidemic in France: the Obepi Surveys 1997–2006. Obesity, 16, 21822186.
De Hert, M. et al. (2006). Prevalence of diabetes, metabolic syndrome and metabolic abnormalities in schizophrenia over the course of the illness: a cross-sectional study. Clinical Practice and Epidemiology in Mental Health, 2, 14. doi: 10.1186/1745-0179-2-14.
Dixon, L. et al. (2000). Prevalence and correlates of diabetes in national schizophrenia samples. Schizophrenia Bulletin, 26, 903912.
Drimer, T. et al. (2004). Effects of discontinuation of long-term anticholinergic treatment in elderly schizophrenia patients. International Clinical Psychopharmacology, 19, 2729.
Friedman, J. I. et al. (2001). Six-year follow-up study of cognitive and functional status across the lifespan in schizophrenia: a comparison with Alzheimer's disease and normal aging. American Journal of Psychiatry, 158, 14411448.
Gray, R. (2005). The NICE guidelines for schizophrenia. Psychiatry, 4, 1113.
Gury, C. (2004). Schizophrénie, diabète et antipsychotiques. L'Encéphale, 30, 382391.
Harvey, P. D. (2001). Cognitive impairment in elderly patients with schizophrenia: age related changes. International Journal of Geriatric Psychiatry, 16, S78S85.
Harvey, P. D. et al. (1998). Symptoms, cognitive functioning, and adaptive skills in geriatric patients with lifelong schizophrenia: a comparison across treatment sites. American Journal of Psychiatry, 155, 10801086.
Hennekens, C. H. et al. (2005). Schizophrenia and increased risks of cardiovascular disease. American Heart Journal, 150, 11151121.
hopital.fr (2010). La Psychiatrie. Available at: http://www.hopital.fr/Hopitaux/L-hopital-et-vous/La-psychiatrie.
Jeste, D. V. et al. (2005). Atypical antipsychotics in elderly patients with dementia or schizophrenia: review of recent literature. Harvard Review of Psychiatry, 13, 340351.
Jones, D. R. et al. (2004). Prevalence, severity, and co-occurrence of chronic physical health problems of persons with serious mental illness. Psychiatric Services, 55, 12501257.
Kusnik-Joinville, O. et al. (2008). Prevalence and treatment of diabetes in France: trends between 2000 and 2005. Diabetes and Metabolism, 34, 266272.
Lefebvre, N. et al. (2006). Comorbidités somatiques chez les patients souffrant de schizophrenie traitée: recommandations actuelles. Annales Medico-psychologiques, Revue Psychiatrique, 164, 159164.
Lehman, A. F. et al. (2004a). The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2003. Schizophrenia Bulletin, 30, 193217.
Lehman, A. F., Lieberman, J. A., Dixon, L. B., McGlashan, T. H., Miller, A. L., Perkins, D. O. and Kreyenbuhl, J. for the American Psychiatric Association; Steering Committee on Practice Guidelines (2004b). Practice guideline for the treatment of patients with schizophrenia, second edition. American Journal of Psychiatry, 161 (Suppl. 2), 156.
Limosin, F. (2009). Schizophrenia and the elderly patient. L'Encéphale, 35 (Suppl. 1), S41S44.
Marder, S. R. et al. (2004). Physical health monitoring of patients with schizophrenia. American Journal of Psychiatry, 161, 13341349.
Masand, P. S. and Gupta, S. (2003). Long-acting injectable antipsychotics in the elderly: guidelines for effective use. Drugs and Aging, 20, 10991110.
McEvoy, J. P. et al. (2005). Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophrenia Research, 80, 1932.
Nasrallah, H. A. et al. (2006). Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline. Schizophrenia Research, 86, 1522.
Rosenheck, R. A. et al. (2006). Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia. American Journal of Psychiatry, 163, 20802089.
Ruetsch, O., Viala, A., Bardou, H., Martin, P., Vacheron, M. N. (2005). Prise de poids pharmaco-induite par les psychotropes et sa prise en charge: revue des données de la littérature. L'Encéphale, 31, 507516.
Sokal, J. et al. (2004). Comorbidity of medical illnesses among adults with serious mental illness who are receiving community psychiatric services. Journal of Nervous Mental Disorders, 192, 421427.
Thorpe, L. (1997). The treatment of psychotic disorders in late life. Canadian Journal of Psychiatry, 42 (Suppl. 1), S19S27.
White, L. et al. (2006). Long-term outcomes in chronically hospitalized geriatric patients with schizophrenia: retrospective comparison of first generation and second generation antipsychotics. Schizophrenia Research, 88, 127134.
WHO (2007). ICD-10: Mental and Behavioural Disorders. Geneva: World Health Organization.
Wirshing, D. A., Pierre, J. M., Erhart, S. M., Boyd, J. A. (2003). Understanding the new and evolving profile of adverse drug effects in schizophrenia. Psychiatric Clinics of North America, 26, 165190.
Wooltorton, E. (2002). Risperidone (Risperdal): increased rate of cerebrovascular events in dementia trials. Canadian Medical Association Journal, 167, 12691270.
Wooltorton, E. (2004). Olanzapine (Zyprexa): increased incidence of cerebrovascular events in dementia trials. Canadian Medical Association Journal, 170, 1395.

Keywords

Health management of older persons with chronically medicated psychotic disorders: the results of a survey in France

  • Christophe Arbus (a1), Jean-Pierre Clement (a2), Thierry Bougerol (a3), Patrick Fremont (a4), Sylvie Lancrenon (a5) and Vincent Camus (a6)...

Metrics

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed